ArticleGeroScience2026
Biological age acceleration, longitudinal change and mortality risk in the Dutch Lifelines cohort.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accelerated biological aging has been associated with mortality, but it remains unclear whether longitudinal changes in age acceleration predict long-term mortality risk. In the population-based Dutch Lifelines cohort, we estimated biological age using the Klemera-Doubal method (KDM-BA) and derived KDM-BA acceleration at baseline and follow-up. We examined baseline acceleration (continuous and categorical: < - 1, - 1 to 1 [reference], > 1 year), annual change in acceleration and four aging trajectory groups. Associations with all-cause mortality were assessed using Cox models adjusted for age, sex, socioeconomic status and lifestyle factors. Among 90,632 participants (3,976 deaths; median follow-up 13.8 years), higher baseline KDM-BA acceleration was associated with higher mortality (HR per 1-year increase = 1.07; 95% CI: 1.06-1.08); acceleration > 1 year predicted higher mortality risk (HR = 1.31; 95% CI: 1.21-1.42) compared with - 1 to 1 years. Among 25,752 participants with repeated assessments (879 deaths; median baseline-to-follow-up 4.3 years), a greater annual increase in acceleration was associated with higher mortality (HR per 1-year/year increase = 1.21; 95% CI: 1.07-1.37), and persistent accelerated aging showed the highest risk (HR = 1.39; 95% CI: 1.19-1.62) compared with stable non-accelerated aging. Higher baseline KDM-BA acceleration and worsening acceleration over time were associated with higher long-term all-cause mortality, supporting repeated clinical assessment to monitor biological aging in population settings.
Indexed as
Identifiers
41981354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.